Bioethics News

HCV Drugs Cost-Effective, But Who Should Get Them?

(Medscape) – Expensive new drugs for hepatitis C virus (HCV) are cost-effective for most patients, according to two new studies published in the March 17 issue of the Annals of Internal Medicine. However, the authors of one study add that paying for the drugs is unsustainable with current resources and growing demand. The studies stir the debate about who should get the drugs, who should pay, and whether a traditional cost-effectiveness analysis is really the measure that should be used.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.